Microsoft PowerPoint - Roche IR Event EULAR Final.ppt

More documents

Recommendations

Info

Demographics Intent-to-treat population Placebo (MTX only) (n=204) Tocilizumab 4 mg/kg + MTX (n=213) Tocilizumab 8 mg/kg + MTX (n=205) Female (%) 78 82 85 Age (mean, yrs) 50.6 51.4 50.8 RF positive (%) 74 82 87 Mean MTX dose (mg/wk) 14.9 14.8 14.6 Previous DMARDs (mean number)* 1.7 1.5 1.5 Prior anti-TNF treatment (%)** 9 10 5 Concomitant steroids (%) 54 55 55 Concomitant NSAIDs (%) 68 68 66 *Not counting MTX **Discontinued for reasons other than lack of efficacy 18
Patients’ baseline disease characteristics Placebo (MTX only) (n=204) Tocilizumab 4 mg/kg + MTX (n=213) Tocilizumab 8 mg/kg + MTX (n=205) Disease duration (mean, yrs) 7.8 7.4 7.5 SJC (mean) 20.7 20.0 19.5 TJC (mean) 32.8 33.2 31.9 CRP (mean, mg/dL) 2.36 2.79 2.61 ESR (mean, mm/h) 49.7 49.2 51.2 DAS28 (mean) 6.82 6.78 6.82 19
Page 2 and 3: Roche Analyst Meeting EULAR 2007 Ba
Page 4 and 5: Introduction Dr. Karl Mahler Head o
Page 6 and 7: Roche’s key therapeutic areas Cur
Page 8 and 9: RA: A very concentrated market 6.00
Page 10 and 11: Increased penetration of biologics
Page 12 and 13: Actemra: The OPTION trial results P
Page 14 and 15: Elevated IL-6 plays central role in
Page 16 and 17: The OPTION study TOcilizumab Pivota
Page 20 and 21: Results: Efficacy and safety 20
Page 22 and 23: Rapid onset of action with tocilizu
Page 24 and 25: Tocilizumab induces rapid CRP norma
Page 26 and 27: Most frequently reported AEs Incide
Page 28 and 29: Adverse events Consistent with thos
Page 30 and 31: MabThera: Longer-term repeat treatm
Page 32 and 33: Rituximab selectively targets CD20-
Page 34 and 35: Rituximab: Advancing in RA Initial
Page 36 and 37: Inhibition of radiographic progress
Page 38 and 39: Efficacy: Repeat treatment courses
Page 40 and 41: Patient exposure to repeat courses
Page 42 and 43: ACR scores are sustained Repeated c
Page 44 and 45: Consistent time intervals between t
Page 46 and 47: More than 2400 patient-years As of
Page 48 and 49: No increase in infection rates with
Page 50 and 51: IgM RF levels by treatment course o
Page 52 and 53: Rates of serious infection Similar
Page 54 and 55: Roche’s franchise in autoimmune d
Page 56 and 57: Overview of autoimmune disorders IN
Page 58 and 59: Not all patients respond to current
Page 60 and 61: Major players are active in this ar
Page 62 and 63: Actemra Potential to become a signi
Page 64 and 65: Ocrelizumab in autoimmune diseases
Page 66 and 67: Multiple sclerosis An emerging ther
Page 68 and 69:
Prevalence of MS in Europe ~260,000
Page 70 and 71:
Development hurdles & treatment cha
Page 72 and 73:
Roche in autoimmune disorders Roche
show all

Microsoft PowerPoint - Roche IR Event EULAR Final.ppt

Create successful ePaper yourself

Delete template?

Save as template?